Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.

New Trials Available at UVA

Amyotrophic Lateral Sclerosis (IRB-HSR #21602)

Open-label, Non-Randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol Citrate 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS) who have Completed the ORARIALS-01 Trial (NCT03836716)

Primary Investigator: Matthew Elliott

Clinical Research Coordinator: Mary Wagoner

Genitourinary Oncology (IRB-HSR #21771)

A Multicenter Phase IIb Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane (NCT04028388)

Primary Investigator: Robert Dreicer

Hematologic Malignancies (IRB-HSR #21781)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT03657160)

Primary Investigator: Leonid Volodin

Clinical Research Coordinator: Megan Healy

Hematologic Malignancies (IRB-HSR #21795)

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Primary Investigator: Laahn Foster

Clinial Research Coordinator: Sharon Johnson

Myasthenia Gravis (IRB-HSR #21943)

A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness (NCT03770403)

Primary Investigator: Sarah Jones

Clinical Research Coordinator: Mary Wagoner

Hematologic Malignancies (IRB-HSR #21188)

Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia (NCT03258931)

Primary Investigator: Michael Keng

Genitourinary Oncology (IRB-HSR #21680)

A Phase II trial of sEphB4-HSA in combination with ANti PD1 Antibody Pembrolizumab (MK-3475) for metastatic urothelial cancer refractory to platinum. (NCT02717156)

Primary Investigator: Michael Devitt

Clinical Research Coordinator: Jennifer Drake

Hematologic Malignancies (IRB-HSR #21781)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT03657160)

Primary Investigator: Leonid Volodin

Clinical Research Coordinator: Megan Healy

Melanoma (IRB-HSR #21850)

Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320)

Primary Investigator: Lynn Dengel

Clinical Research Coordinator: Rachael Reed

Transplant (IRB-HSR #20915)

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies (NCT02730299)

Primary Investigator: Leonid Volodin

B-cell Acute Lymphoblastic Leukemia (IRB-HSR #21417)

Phase I Study of Inotuzumab Ozogamicin with 3 and 4 Drug Augmented Berlin-Frankfurt-M├╝nster (BFM) Re-Induction for Younger Adults Ages 18-55 with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03962465)

Primary Investigator: Michael Douvas

Clinical Research Coordinator: Cara Hanby

Colorectal Cancer (IRB-HSR #21923)

A Phase Ib/2, Open-Label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-Line Therapy in Metastatic Microsatellite-Stable Colorectal Cancer (COLUMBIA-1) (NCT04068610)

Primary Investigator: Matthew Reilley

Clinical Research Coordinator: Sallie Mannen

Breast Oncology (IRB-HSR #21822)

COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer (NCT04038489)

Primary Investigator: Patrick Dillon

Clinical Research Coordinator: Jake Boyd

Hematologic Malignancies IRB-HSR #21776

Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age. PrECOG Protocol Number: PrE0405. (NCT03834688)

Primary Investigator: Craig Portell

Thoracic Oncology (IRB-HSR #21811)

Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 and a CTLA-4 inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects with Non-small Cell Lung Cancer or Urothelial Cancer (NCT03989362)

Primary Investigator: Ryan Gentzler

Clinical Research Coordinator: Gracie Hockenberry

 

Thoracic Oncology (IRB-HSR #21913)

A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) (NCT03971474)

Primary Investigator: Richard Hall

Clinical Research Coordinator: Gracie Hockenberry